Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French and Belgian researchers team up

This article was originally published in Scrip

Executive Summary

Lyonbiopole and Biowin, two healthcare competitiveness clusters in France and Belgium respectively, have concluded a collaboration agreement that will allow for inter-cluster partnerships in R&D, training and communication. The two groups are setting up the Prediction research programme to predict the safety of new biologicals capable of targeting the immune system, allowing toxicology assessments at an early stage in the development process. Initially, projects will be developed with regional or national funds and then consolidated in a European framework. Training modules might also be consolidated at European level, after the specific needs of each cluster have been inventoried. Raising the general public's awareness of medicine, biotechnology and medical technology through a communication programme is also a joint commitment of the two clusters. Lyonbiopole was set up as a cluster in 2005 as part of a government initiative to increase France's competitiveness. The Walloon regional government in Belgium approved Biowin in 2006, setting its focus on cancer, inflammation and brain diseases.

You may also be interested in...

Cervarix link to UK girl's death "unlikely"

Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.

Generic Topamax launched in European markets

Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.

NICE confirms limits on Alimta for lung cancer

Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts